{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:45:27Z","timestamp":1780451127359,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11504-2","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:50:39Z","timestamp":1758876639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Continuous versus intermittent infusion of \u03b2-lactams in patients with sepsis and septic shock: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"David A.","family":"Tejada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel C.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Tom\u00e1s-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Yangali-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Rivera-Lozada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshuan J.","family":"Barboza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"11504_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11111508","volume":"11","author":"D Hyun","year":"2022","unstructured":"Hyun D, Seo J, Lee SY, et al. Continuous piperacillin-tazobactam infusion improves clinical outcomes in critically ill patients with sepsis: a retrospective, single-centre study. Antibiotics. 2022;11: 1508. https:\/\/doi.org\/10.3390\/antibiotics11111508.","journal-title":"Antibiotics"},{"key":"11504_CR2","doi-asserted-by":"publisher","unstructured":"I M-L RF. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42. https:\/\/doi.org\/10.1097\/CCM.0000000000000330.","DOI":"10.1097\/CCM.0000000000000330"},{"key":"11504_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014632","volume":"98","author":"C-H Chen","year":"2019","unstructured":"Chen C-H, Chen Y-M, Chang Y-J, et al. Continuous versus intermittent infusions of antibiotics for the treatment of infectious diseases. Medicine (Baltimore). 2019;98: e14632. https:\/\/doi.org\/10.1097\/MD.0000000000014632.","journal-title":"Medicine (Baltimore)"},{"key":"11504_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11111508","volume":"11","author":"D-G Hyun","year":"2022","unstructured":"Hyun D-G, Seo J, Lee SY, et al. Continuous piperacillin-tazobactam infusion improves clinical outcomes in critically ill patients with sepsis: a retrospective, single-centre study. Antibiotics. 2022;11: 1508. https:\/\/doi.org\/10.3390\/antibiotics11111508.","journal-title":"Antibiotics"},{"key":"11504_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12879-020-05149-6","volume":"20","author":"S Fawaz","year":"2020","unstructured":"Fawaz S, Barton S, Nabhani-Gebara S. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis. BMC Infect Dis. 2020;20:430. https:\/\/doi.org\/10.1186\/s12879-020-05149-6.","journal-title":"BMC Infect Dis"},{"key":"11504_CR6","doi-asserted-by":"publisher","unstructured":"H S, B F, B T, et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med. 2022;48. https:\/\/doi.org\/10.1007\/s00134-021-06609-6.","DOI":"10.1007\/s00134-021-06609-6"},{"key":"11504_CR7","doi-asserted-by":"publisher","unstructured":"Aardema H, Bult W, Van Hateren K, et al. Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations. J Antimicrob Chemother. 2019;dkz463. https:\/\/doi.org\/10.1093\/jac\/dkz463.","DOI":"10.1093\/jac\/dkz463"},{"key":"11504_CR8","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","volume":"42","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH, Sulaiman H, Mat-Nor M-B, et al. Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42:1535\u201345. https:\/\/doi.org\/10.1007\/s00134-015-4188-0.","journal-title":"Intensive Care Med"},{"key":"11504_CR9","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/cc11405","volume":"16","author":"I Chytra","year":"2012","unstructured":"Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012;16:R113. https:\/\/doi.org\/10.1186\/cc11405.","journal-title":"Crit Care"},{"key":"11504_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2024.9779","volume":"332","author":"JM Dulhunty","year":"2024","unstructured":"Dulhunty JM, Brett SJ, De Waele JJ, et al. Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial. JAMA. 2024;332:629\u201337. https:\/\/doi.org\/10.1001\/jama.2024.9779.","journal-title":"JAMA"},{"key":"11504_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/cid\/cis856","volume":"56","author":"JM Dulhunty","year":"2013","unstructured":"Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of Beta-Lactam antibiotics in severe sepsis: A multicenter Double-Blind, randomized controlled trial. Clin Infect Dis. 2013;56:236\u201344. https:\/\/doi.org\/10.1093\/cid\/cis856.","journal-title":"Clin Infect Dis"},{"key":"11504_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","volume":"192","author":"JM Dulhunty","year":"2015","unstructured":"Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192:1298\u2013305. https:\/\/doi.org\/10.1164\/rccm.201505-0857OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"11504_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","volume":"48","author":"S Hagel","year":"2022","unstructured":"Hagel S, Bach F, Brenner T, et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med. 2022;48:311\u201321. https:\/\/doi.org\/10.1007\/s00134-021-06609-6.","journal-title":"Intensive Care Med"},{"key":"11504_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106487","volume":"90","author":"AB Khan","year":"2025","unstructured":"Khan AB, Abdul-Aziz MH, Hindle L, et al. Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: a randomized controlled trial. J Infect. 2025;90: 106487. https:\/\/doi.org\/10.1016\/j.jinf.2025.106487.","journal-title":"J Infect"},{"key":"11504_CR15","doi-asserted-by":"publisher","unstructured":"Monti G, Bradic N, Marzaroli M, et al. Continuous vs intermittent meropenem administration in critically Ill patients with sepsis: The Mercy randomized clinical trial. JAMA. 2023;330(2):141\u2013151. https:\/\/doi.org\/10.1001\/jama.2023.10598.","DOI":"10.1001\/jama.2023.10598"},{"key":"11504_CR16","doi-asserted-by":"publisher","first-page":"0","DOI":"10.21608\/bmfj.2023.247556.1949","volume":"0","author":"S Saad","year":"2023","unstructured":"Saad S, Aglan B, Shaboob E, et al. Continuous versus intermittent use of meropenem in septic critically ill patients: A randomized controlled trail. Benha Med J. 2023;0:0\u20130. https:\/\/doi.org\/10.21608\/bmfj.2023.247556.1949.","journal-title":"Benha Med J"},{"key":"11504_CR17","doi-asserted-by":"publisher","unstructured":"Zhao HY, Gu J, Lyu J, et al. Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: A prospective randomized pilot study. Chin Med J (Engl). 2017;130(10):1139\u20131145. https:\/\/doi.org\/10.4103\/0366-6999.205859.","DOI":"10.4103\/0366-6999.205859"},{"key":"11504_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13613-024-01263-9","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zang B, Wang Q. Prolonged versus intermittent \u03b2-lactam infusion in sepsis: a systematic review and meta-analysis of randomized controlled trials. Ann Intensive Care. 2024;14:30. https:\/\/doi.org\/10.1186\/s13613-024-01263-9.","journal-title":"Ann Intensive Care"},{"key":"11504_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.17219\/acem\/121934","volume":"29","author":"P Chen","year":"2020","unstructured":"Chen P, Chen F, Lei J, et al. Clinical outcomes of continuous vs intermittent meropenem infusion for the treatment of sepsis: a systematic review and meta-analysis. Adv Clin Exp Med. 2020;29:993\u20131000. https:\/\/doi.org\/10.17219\/acem\/121934.","journal-title":"Adv Clin Exp Med"},{"key":"11504_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/antibiotics12061024","volume":"12","author":"K Ishikawa","year":"2023","unstructured":"Ishikawa K, Shibutani K, Kawai F, et al. Effectiveness of extended or continuous vs. bolus infusion of broad-spectrum beta-lactam antibiotics for febrile neutropenia: a systematic review and meta-analysis. Antibiotics. 2023;12:1024. https:\/\/doi.org\/10.3390\/antibiotics12061024.","journal-title":"Antibiotics"},{"key":"11504_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","volume":"332","author":"MH Abdul-Aziz","year":"2024","unstructured":"Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis. JAMA. 2024;332:638\u201348. https:\/\/doi.org\/10.1001\/jama.2024.9803.","journal-title":"JAMA"},{"key":"11504_CR22","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre P-F, Dugernier T, et al. Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:R126. https:\/\/doi.org\/10.1186\/cc9091.","journal-title":"Crit Care"},{"key":"11504_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/phar.2753","volume":"43","author":"P Williams","year":"2023","unstructured":"Williams P, Cotta MO, Abdul-Aziz MH, et al. In Silico evaluation of a beta\u2010lactam dosing guideline among adults with serious infections. Pharmacotherapy. 2023;43:1121\u201330. https:\/\/doi.org\/10.1002\/phar.2753.","journal-title":"Pharmacotherapy"},{"key":"11504_CR24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jiac.2024.07.003","volume":"30","author":"H Hagiya","year":"2024","unstructured":"Hagiya H. Detailed regimens for the prolonged \u03b2-lactam infusion therapy. J Infect Chemother. 2024;30:1324\u20136. https:\/\/doi.org\/10.1016\/j.jiac.2024.07.003.","journal-title":"J Infect Chemother"},{"key":"11504_CR25","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1093\/jac\/dkac273","volume":"77","author":"CD Sumi","year":"2022","unstructured":"Sumi CD, Heffernan AJ, Naicker S, et al. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin\/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates. J Antimicrob Chemother. 2022;77:3026\u201334. https:\/\/doi.org\/10.1093\/jac\/dkac273.","journal-title":"J Antimicrob Chemother"},{"key":"11504_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijantimicag.2009.10.008","volume":"35","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Kirkpatrick CMJ, Roberts MS, et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of Piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010;35:156\u201363. https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.10.008.","journal-title":"Int J Antimicrob Agents"},{"key":"11504_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcrc.2018.08.026","volume":"48","author":"C Carri\u00e9","year":"2018","unstructured":"Carri\u00e9 C, Legeron R, Petit L, et al. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion. J Crit Care. 2018;48:66\u201371. https:\/\/doi.org\/10.1016\/j.jcrc.2018.08.026.","journal-title":"J Crit Care"},{"key":"11504_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121567","volume":"320","author":"SG Passon","year":"2023","unstructured":"Passon SG, Schmidt AR, Wittmann M, et al. Evaluation of continuous ampicillin\/sulbactam infusion in critically ill patients. Life Sci. 2023;320: 121567. https:\/\/doi.org\/10.1016\/j.lfs.2023.121567.","journal-title":"Life Sci"},{"key":"11504_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13613-023-01222-w","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Long Y, Wu G, et al. Prolonged vs intermittent intravenous infusion of \u03b2-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. Ann Intensive Care. 2023;13:121. https:\/\/doi.org\/10.1186\/s13613-023-01222-w.","journal-title":"Ann Intensive Care"},{"key":"11504_CR30","doi-asserted-by":"publisher","unstructured":"Lokhandwala A, Patel P, Isaak AK et al. Comparison of the effectiveness of prolonged infusion and intermittent infusion of meropenem in patients with sepsis: A Meta-Analysis. Cureus N D;15:e46990. https:\/\/doi.org\/10.7759\/cureus.46990","DOI":"10.7759\/cureus.46990"}],"updated-by":[{"DOI":"10.1186\/s12879-025-12213-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11504-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:38:38Z","timestamp":1768631918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11504-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11504"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11504-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-025-12213-6","URL":"https:\/\/doi.org\/10.1186\/s12879-025-12213-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}}],"article-number":"1138"}}